Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Semaglutide vs empagliflozin vs combination therapy in type 2 diabetes mellitus with nonalcoholic fatty liver disease
ChiCTR2300070674Phase 4Not yet recruiting
- Sponsor
- Xiamen Humanity Hospital
- Start
- Apr 2023
- Modality
- Recombinant Proteins and Enzymes, Peptides, Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of semaglutide and empagliflozin in metabolic dysfunction-associated steatotic liver disease (MASLD) and type 2 diabetes mellitus (T2DM) (3 arms), sponsored by Xiamen Humanity Hospital. Primary endpoints: Degree of fatty liver at 52 weeks, Glucagon level at 52 weeks and 2 more. Planned start Apr 2023; status: not yet recruiting.
02
Drugs
semaglutideempagliflozin
03
Conditions
metabolic dysfunction-associated steatotic liver disease (MASLD)type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on ChiCTR2300070674.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2300070674.